Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era

Liset Olarte*, William J. Barson, Ryan M. Barson, José R. Romero, John S. Bradley, Tina Q. Tan, Laurence B. Givner, Jill A. Hoffman, Philana Ling Lin, Kristina G. Hultén, Edward O. Mason, Sheldon L. Kaplan

*Corresponding author for this work

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Background. The impact of PCV13 on a number of clinical aspects of pneumococcal pneumonia (PP) in children has not been reported. We compared the serotype distribution, antibiotic susceptibility, and outcomes of children with PP 4 years before and 4 years after the introduction of PCV13. Methods. We identified patients ≤18 years with PP at 8 children's hospitals in the United States (2006-2014). Pneumococcal isolates were collected prospectively. Serotyping and antibiotic susceptibility were performed in a central laboratory. Clinical and laboratory data were collected retrospectively. Annual pneumococcal pneumonia hospitalization rates per 100 000 admissions with 95% confidence intervals were calculated. Dichotomous variables were analyzed by Ï ‡ 2 test and continuous variables with Mann-Whitney U test. Results. A total of 377 patients with PP requiring hospitalization were identified. Hospitalization rates of PP decreased from 53.6 to 23.3 per 100000 admissions post PCV13 (P <.0001). Complicated PP rates also decreased (P <.0001). Need for intensive care, mechanical ventilation, and invasive procedure remained unchanged after the introduction of PCV13. Comorbidities were more common among children with uncomplicated than complicated pneumonia (52.2% vs. 22.5%, P <.001). Overall, PCV13 serotypes 19A, 3, 7F, and 1 caused 80% of PP. Hospitalization rates of PCV13 serotype pneumonia decreased from 47.2 to 15.7 per 100000 admissions post PCV13. In 2014, the most common serotypes were 3, 19A and 35B. Conclusions. PP requiring hospitalization significantly decreased in children after PCV13 introduction. Complicated PP rates decreased steadily in 2011-2014. PCV13 serotypes 19A and 3 were still responsible for half of the cases of PP in 2011-2014.

Original languageEnglish (US)
Pages (from-to)1699-1704
Number of pages6
JournalClinical Infectious Diseases
Volume64
Issue number12
DOIs
StatePublished - Jun 15 2017

Keywords

  • PCV13
  • Streptococcus pneumoniae
  • empyema
  • pneumococcal disease.
  • pneumonia

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era'. Together they form a unique fingerprint.

  • Cite this

    Olarte, L., Barson, W. J., Barson, R. M., Romero, J. R., Bradley, J. S., Tan, T. Q., Givner, L. B., Hoffman, J. A., Lin, P. L., Hultén, K. G., Mason, E. O., & Kaplan, S. L. (2017). Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era. Clinical Infectious Diseases, 64(12), 1699-1704. https://doi.org/10.1093/cid/cix115